Perioperative and adjuvant chemotherapy on survival in advanced gastric cancer following gastrectomy with D2 lymphadenectomy

• Autores: Luna-Córdova, Cesia J., Díaz-Plasencia, Juan Alberto, Yan-Quiroz, Edgar Fermín, Tenazoa-Villalobos, José Richard
• Formato: artículo
• Fecha de Publicación: 2025
• Institución: Sociedad de Gastroenterología del Perú
• Repositorio: Revista de Gastroenterología del Perú
• Lenguaje: español
• OAI Identifier: oai:ojs.revistagastroperu.com:article/1762
• Enlace del recurso: https://revistagastroperu.com/index.php/rgp/article/view/1762
• Nivel de acceso: acceso abierto
• Materia: Neoplasias Gástricas; Gastrectomía; Escisión del Ganglio Linfático; Quimioterapia; Quimioterapia Adyuvante; Sobrevida; Stomach Neoplasms; Gastrectomy; Lymph Node Excision; Drug Therapy; Chemotherapy, Adjuvant; survival

Objective: To describe the effectiveness of perioperative chemotherapy and adjuvant chemotherapy in the survival of patients with gastric carcinoma after gastrectomy with D2 lymphadenectomy (T2-T4a) and to determine the association between the intervening factors of the study and the survival of this group. Materials and methods: Observational study, retrospective cohorts, in patients who received perioperative or adjuvant chemotherapy at a Peruvian cancer institute from January 2007 to December 2022. To determine actuarial survival, the Kaplan-Meier method and the log-rank test were used to compare 2 survival curves. Results: A total population of 82 patients was evaluated, of which 46 received adjuvant chemotherapy and 36 perioperative chemotherapy, with the most commonly used regimen being CAPOX and EOX/EOX, respectively. Clinical characteristics did not significantly influence overall survival and only the primary tumor (T) had a statistically significant association, with T4a being more frequent in the perioperative chemotherapy group than in the adjuvant modality group (80.6% vs 47.8%; p=0.002). When comparing both therapeutic modalities, it was evident that patients who received perioperative chemotherapy had a longer survival at 5 years (53.2%), however, this was not statistically significant (p=0.230). Conclusions: Perioperative chemotherapy presented greater survival compared to adjuvant chemotherapy at 12, 36 and 60 months; however, these differences were not statistically significant.